BDH Industries Ltd.
BSE: BDH · Pharmaceuticals · sector
₹411.30BSE close 2026-10-26
Key numbers
Market cap₹237 cr
Price₹411.30
52w high / low₹610 / ₹340
P/E20.2xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹133.8
Dividend yield1.09%Sector median 0.48%
ROE16.1%Sector median 11.7%
ROCE20.9%Sector median 12.3%
OPM15.3%Sector median 14.0%
Debt / equity0.03xSector median 0.16x
EV/EBITDA13.8xSector median 18.6x
Interest cover239.4x
Current ratio4.00x
Sales growth 3y+8.8%Sector median +9.6%
Profit growth 3y+9.6%Sector median +13.3%
PEG2.10x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹29 cr vs borrowings ₹2 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 239.4x in the last 12 months.
- Other income was 18% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹411.30 on 2026-10-26: -32.6% from the 52-week high, +20.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹564.55 · low ₹247.10
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 18 | 19 | 19 | 29 | 29 | 22 |
| EBITDA | 3 | 2 | 3 | 4 | 4 | 3 |
| OPM % | 17.2% | 11.4% | 17.6% | 14.4% | 14.5% | 15.5% |
| Other income | 1 | 1 | 1 | 1 | 1 | 0 |
| Net profit | 2 | 2 | 3 | 3 | 3 | 3 |
| EPS (₹) | 4.33 | 3.17 | 4.55 | 6.06 | 5.00 | 4.73 |
| Revenue YoY | +62.9% | +20.2% | ||||
| Profit YoY | +15.7% | +48.6% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 69 | 74 | 86 | 67 | 96 | 100 |
| EBITDA | 10 | 11 | 12 | 12 | 14 | 15 |
| Net profit | 7 | 8 | 10 | 9 | 11 | 12 |
| EPS (₹) | 12.55 | 14.25 | 17.14 | 16.11 | 18.78 | 20.34 |
| Revenue growth | +7.3% | +15.3% | -22.5% | +44.3% | – | |
| Profit growth | +13.7% | +20.2% | -6.1% | +16.6% | – | |
| Dividend / share (₹) | – | 3.60 | 4.00 | 4.50 | 4.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +8.8% | – | – |
| Net profit | +9.6% | – | – |
| EPS | +9.6% | – | – |
| Share price | – | +18.0% (2y) | +0.3% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 69 | 77 |
| Borrowings | 1 | 2 |
| Cash & equivalents | 31 | 29 |
| Total assets | 87 | 99 |
| Fixed assets | 20 | 19 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 14 | 32 |
| Inventory | 7 | 5 |
| Payables | 15 | 17 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 15 | -2 |
| Cash from investing | 2 | 2 |
| Cash from financing | -10 | -2 |
| Capex | 0 | 0 |
| Free cash flow | 15 | -2 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 13.5% | 14.0% |
| ROCE % | 18.0% | 19.3% |
| Debtor days | 78 | 120 |
| Inventory days | 65 | 28 |
| Payable days | 134 | 91 |
| Cash conversion cycle (days) | 9 | 57 |
| Working capital days | 273 | 228 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BDH | ₹237 cr | 20.2x | 3.1x | 16.1% | 20.9% | 15.3% | +8.8% | 1.09% |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| PHARMACEUTICAL | ₹22 cr | 98.4% | ₹4 cr | 15.8% |
| RENEWABLE ENERGY | ₹0 cr | 1.6% | ₹0 cr | 64.2% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-07 | Dividend | Final Dividend Rs 5.0 |
| 2025-08-01 | Dividend | Final Dividend Rs 4.5 |
| 2024-08-02 | Dividend | Final Dividend Rs 4.5 |
| 2023-08-02 | Dividend | Final Dividend Rs 4.0 |
| 2022-08-12 | Dividend | Final Dividend Rs 3.6 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BDH |
| BSE code | 524828 |
| ISIN | INE278D01018 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.